|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Analysts expect Pfizer’s (PFE) top line to increase ~2.9% to ~$13.5 billion during the third quarter. The company’s EPS is expected to increase to $0.75 in the third quarter—compared to $0.67 in the third quarter of 2017.
As we discussed earlier, analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to revenues of $13.2 billion during the third quarter of 2017. The revenue growth is expected to be driven by innovative health products’ strong performance.
Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.
Novartis (NVS), one of the leading healthcare companies, released its third-quarter earnings on October 18. Novartis surpassed Wall Street analysts’ estimates for EPS but missed estimates for revenues with reported EPS of $1.32 on revenues of ~$12.78 billion as compared to the estimated EPS of $1.31 on revenues of ~$13.02 billion during the third quarter of 2018.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet
Johnson & Johnson (NYSE:JNJ) has rallied nicely since the summer. JNJ stock touched a 15-month low in late May — but it’s rallied nicely. Johnson & Johnson stock touched an eight-month high last month before a modest pullback of late.
Centrexion Therapeutics Corp., a pain treatment developer founded by the former leaders of Pfizer Inc. and Celgene Corp., on Friday disclosed plans to go public.
Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
As the Dow Jones Industrial Average (DJIA) index experiences a period of heightened volatility, healthcare stocks have proved relatively immune to the wider market swings. Healthcare players Pfizer Inc. ( PFE), UnitedHealth Group Inc. ( UNH) and Merck & Co., Inc. ( MRK), all members of the blue chip index, remain within short reach of their 52-week highs, while the DJIA has fallen 5.8% from its own as of Friday afternoon.
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies. The drug stores were said to have bought large quantities of the drug and agreed to limit re-supply of competing generic atorvastatin products.
Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies.
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.